<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893451</url>
  </required_header>
  <id_info>
    <org_study_id>VitaD-CKD1</org_study_id>
    <nct_id>NCT00893451</nct_id>
  </id_info>
  <brief_title>Study of Vitamin D3 Supplementation in Patients With Chronic Kidney Disease</brief_title>
  <acronym>VitaD-CKD1</acronym>
  <official_title>Does Vitamin D3 (Cholecalciferol) Supplementation Change Insulin Resistance in Patients With Chronic Kidney Disease?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of vitamin D3 supplementation on the&#xD;
      insulin resistance in non-diabetic patients with chronic kidney disease (CKD) stages 3-4,&#xD;
      vitamin D deficiency/insufficiency and elevated fasting serum insulin levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin resistance, i.e., reduction in insulin responsiveness with a decrease in glucose&#xD;
      uptake in insulin target tissues (muscle and adipose tissue) is common in end-stage renal&#xD;
      disease (ESRD), but is also present at earlier stages of renal disease with mild-moderate&#xD;
      renal function impairment as well as in microalbuminuria and nephrotic syndrome.&#xD;
&#xD;
      Population-based cross-sectional studies have shown that low levels of vitamin D (25(OH)&#xD;
      vitamin D) is associated with impaired glucose tolerance in subjects with normal renal&#xD;
      function and that reduced renal function and 25(OH) vitamin D deficiency are independently&#xD;
      associated with insulin resistance.&#xD;
&#xD;
      Vitamin D has well-known effects on calcium metabolism and skeletal mineralisation but recent&#xD;
      experimental studies suggest that vitamin D in addition reduces several inflammatory&#xD;
      mediators that are of importance in the development and progression of renal disease which&#xD;
      also associated with insulin resistance such as TNF-α and IL-6.&#xD;
&#xD;
      This is a prospective, single-blind, explorative, randomized, placebo-controlled,&#xD;
      single-centre, two-way cross-over study with two treatment periods of 10 weeks separated by a&#xD;
      washout period of 6 weeks. Non-diabetic patients with chronic kidney disease (CKD) stage 3&#xD;
      and 4 (GFR 15-60 ml/min/1.73m2) who have low serum 25-OH-vitamin D levels (&lt; 30 ng/mL) and&#xD;
      elevated fasting serum insulin levels (&gt;10 IU/L) will be randomized to receive either vitamin&#xD;
      D3 (cholecalciferol) 3200U orally (tablets) daily or placebo.&#xD;
&#xD;
      Approximately 24 patients are going to complete the study. A pre-entry wash-out period of 6&#xD;
      weeks is needed for patents already on vitamin D treatment. An in vivo assessment of insulin&#xD;
      secretion and insulin sensitivity will be made by insulin-glucose clamp at the end of each&#xD;
      treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in M-value (mg/kg lean body mass/min) assessed by insulin-glucose clamp</measure>
    <time_frame>at week 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in systolic- and diastolic blood pressure</measure>
    <time_frame>at week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PTH secretion and its fragments assessed by PTH, CAP-PTH, CIP-PTH</measure>
    <time_frame>at week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin secretion assessed by intravenous glucose tolerance test</measure>
    <time_frame>at week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary excretion of albumin (UAE) assessed by 24 hour collection</measure>
    <time_frame>at week 26</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Insulin Resistance</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 1600 IU orally twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo orally twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cholecalciferol (TillVal-D)</intervention_name>
    <description>In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>TillVal-D, cholecalciferol, vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo orally twice daily</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, age older than 18 years&#xD;
&#xD;
          2. Non-diabetic chronic kidney disease stage 3 and 4 (GFR 15-60 ml/min/1.73 m2)&#xD;
&#xD;
          3. Serum 25(OH) vitamin D &lt; 30 ng/mL (75 nmol/L)&#xD;
&#xD;
          4. Fasting S-insulin &gt; 30 IU/L&#xD;
&#xD;
          5. Written informed consent before entered into study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with current significant, major or unstable cardio-cerebrovascular,&#xD;
             infection, respiratory, gastrointestinal or other major disease and risks according to&#xD;
             the judgment made by the investigator&#xD;
&#xD;
          2. Patients with type 1 or type 2 Diabetes&#xD;
&#xD;
          3. Current severe thyrotoxicosis or other endocrine disease&#xD;
&#xD;
          4. Granulomatous disease, such as sarcoidosis and tuberculosis&#xD;
&#xD;
          5. Patients who are intended to receive hemodialysis (HD), peritoneal dialysis (PD) or&#xD;
             being kidney transplanted during the course of study (9 months)&#xD;
&#xD;
          6. Concomitant use of corticosteroids (except for inhalation or topical use) or other&#xD;
             immunosuppressive medication&#xD;
&#xD;
          7. Treatment with biphosphonate during last two years&#xD;
&#xD;
          8. S-Calcium &gt; 2.70 mmol/L (0.68 mg/dl)&#xD;
&#xD;
          9. PTH intact &lt; 75 ng/L (8.25 nmol/L) or &gt; 800 ng/L (88 nmol/L)&#xD;
&#xD;
         10. Proteinuria &gt; 3.5 g/24 hours&#xD;
&#xD;
         11. Alcohol or drug abuse or any condition associated with poor compliance&#xD;
&#xD;
         12. Blood donors&#xD;
&#xD;
         13. Women of childbearing potential, desired pregnancy, pregnancy or lactation within the&#xD;
             study period&#xD;
&#xD;
         14. Allergy or intolerance to cholecalciferol supplementation (TillVal D®) or other&#xD;
             constituents&#xD;
&#xD;
         15. Participation in a clinical trial evaluating an investigational drug in the last 12&#xD;
             weeks prior to inclusion to this trial&#xD;
&#xD;
         16. History of kidney stones&#xD;
&#xD;
         17. History of chronic hepatitis or liver enzymes (ASAT or ALAT) more than 2.5 times the&#xD;
             upper limit of normal&#xD;
&#xD;
         18. Gastrointestinal disease resulting in significant gastrointestinal dysfunction or&#xD;
             malabsorption&#xD;
&#xD;
         19. Use of medications known to interact with vitamin D metabolism such as cholestyramine,&#xD;
             phenytoin, digitalis and antacids&#xD;
&#xD;
         20. Planned vacation with &quot;high sun exposure&quot; during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid R Dezfoolian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Kidney diseases, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>May 5, 2009</study_first_submitted>
  <study_first_submitted_qc>May 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>June 9, 2011</last_update_submitted>
  <last_update_submitted_qc>June 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Hamid Dezfoolian, MD</name_title>
    <organization>Dept. of kidney disease, Sahlgrenska University Hospital, Gothenburg, Sweden</organization>
  </responsible_party>
  <keyword>renal disease</keyword>
  <keyword>renal impairment</keyword>
  <keyword>chronic kidney disease stage 3-4</keyword>
  <keyword>25(OH) vitamin D</keyword>
  <keyword>cholecalciferol</keyword>
  <keyword>vitamin D deficiency</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>insulin-glucose clamp</keyword>
  <keyword>non-diabetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

